Korean Man Has Cerebellar Tumor With Two Somatic VHL Variants

A 73-year-old Korean man presented with a spontaneous cerebellar hemangioblastoma whose tumor tissue carried two distinct somatic VHL variants and no detectable germline mutation, a case reported in late November 2026.

The tumor, a 4.5 by 3.9 by 3.2 centimeter cystic lesion with an enhancing mural nodule, compressed the fourth ventricle and was resected after the patient developed symptoms. Pathology confirmed a World Health Organization grade 1 central nervous system hemangioblastoma with 90 percent tumor cellularity.

Next-generation sequencing of the resected tissue identified two pathogenic VHL variants — c.233A>G (p.N78S) at 16 percent variant allele frequency and c.340G>C (p.G114R) at 17 percent — both listed as pathogenic in ClinVar. Germline testing on a buccal sample found no VHL pathogenic variants, and imaging of the chest, abdomen, pelvis, liver, pancreas, and kidneys revealed no systemic neoplasms or cysts.

Two somatic hits without a germline first hit

In classic von Hippel–Lindau disease, patients inherit one defective VHL allele and tumors arise after a “second hit” inactivates the remaining copy. This case departs from that pattern: the two somatic variants were present in the tumor with no germline variant detected, raising the possibility of biallelic somatic inactivation — though phasing was not assessed and matched normal tissue was not sequenced for orthogonal validation.

The patient had no family history of cancer and no clinical stigmata of VHL disease, and the single lesion argues against mosaicism, though low-level mosaicism cannot be excluded.

Age and presentation outside the usual range

Central nervous system hemangioblastomas are diagnosed at a mean age of 51.7 years in sporadic cases and 36.7 years in VHL-associated cases, with 66 percent arising in patients aged 40 or older. This patient’s diagnosis at 73 years places him well above both averages. The lesion was a midline cerebellar cystic mass with a small enhancing mural nodule measuring 1.8 millimeters — an imaging appearance consistent with sporadic hemangioblastoma but occurring at an unusually advanced age.

The patient developed subacute nausea and vomiting associated with a greater than 10 lb weight loss over a few short months. Pre-operative neurological examination was normal. The patient had no concerning family history of cancer.

Systemic imaging showed no lesions concerning for neoplasm or cystic findings to suggest an etiology. Brain MRI revealed a midline cerebellar solid and cystic lesion with an enhancing mural nodule compressing the fourth ventricle. Treatment consisted of craniotomy with gross total resection. Post-operative course included alleviation of symptoms.

Belzutifan context for sporadic disease

Belzutifan, a HIF-2α inhibitor approved for VHL-associated renal cell carcinoma, pancreatic neuroendocrine tumors, and central nervous system hemangioblastomas, has shown radiographic improvement in sporadic CNS hemangioblastomas in two recent case reports — a 23-year-old woman with a posterior fossa tumor and a 33-year-old man with a C7–T1 spinal cord lesion, both treated after surgery and radiation failed. In the spinal case, the tumor shrank from 1.1 by 2.9 centimeters to 0.6 by 1.6 centimeters after eight months on belzutifan.

Those tumors harbored HIF2A mutations, with one also carrying a somatic VHL mutation, suggesting HIF2A as a susceptibility gene in sporadic disease. The current case, by contrast, had two VHL somatic variants and no reported HIF2A alteration, illustrating molecular heterogeneity among sporadic hemangioblastomas that may influence therapeutic response.

On neurological examination, right pupil enlargement was also noted. Because of her prior radiation, focused radiation increased brainstem toxicity. The study concludes that HIF2A should be considered a gene to target for CNS-HB.

Open questions for clinical management

The report notes several limitations: follow-up exceeds one year but remains limited; orthogonal validation, loss-of-heterozygosity analysis, copy-number assessment, VHL promoter methylation testing, and functional studies were not performed. Whether the two variants reside on separate alleles — confirming biallelic inactivation — is unknown. The absence of germline variants on buccal testing does not rule out low-level mosaicism, though no other organ-system abnormalities were found.

For now, the case illustrates that sporadic-appearing CNS hemangioblastomas can present as cystic cerebellar lesions in older adults and can harbor multiple somatic VHL variants without a germline predisposition, a pattern that deepens the molecular picture of these tumors and may inform future use of HIF-2α inhibition beyond VHL-associated disease. The variants’ somatic status and clonal relationship remain uncertain without matched normal tissue and orthogonal validation.